Onureg — CareFirst (Caremark)
Acute Myeloid Leukemia (AML)
Initial criteria
- Member has non-core binding factor (non-CBF) AML
- Requested medication will be used as a single agent
- Member has achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy
- Member is not able to complete intensive curative therapy
Reauthorization criteria
- No evidence of unacceptable toxicity
- No evidence of disease progression while on current regimen
Approval duration
12 months